Echocardiography

Sage Veterinary Imaging Welcomes Dr. Marina Mavromatis

Retrieved on: 
星期三, 十二月 7, 2022
Radio Waves, Heart, Pulse, CT, Echocardiography, American College, ACVR, Skin, MRI, Tufts University, Biopsy, DVM, North Carolina State University, X-ray, Cummings School of Veterinary Medicine, Heart Health Park, Multimedia, Degenerative disease, Veterinary medicine, Magnetic resonance imaging, SVI, Medical imaging, Distribution (marketing)

ROUND ROCK, Texas, Dec. 7, 2022 /PRNewswire/ -- Sage Veterinary Imaging (SVI) has welcomed Marina Mavromatis, DVM, DACVR to its team of veterinary radiologists.

Key Points: 
  • ROUND ROCK, Texas, Dec. 7, 2022 /PRNewswire/ -- Sage Veterinary Imaging (SVI) has welcomed Marina Mavromatis, DVM, DACVR to its team of veterinary radiologists.
  • Dr. Sage has a vision to always push to a higher level of veterinary radiology.
  • In addition to serving as a resource for referring veterinarians in need of human-quality imaging, Dr. Mavromatis will participate in the SVI residency program, training and mentoring diagnostic imaging interns and residents.
  • Sage Veterinary Imaging is accredited by the American College of Veterinary Radiology (ACVR) and includes:
    3T magnetic resonance imaging (MRI).

Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA

Retrieved on: 
星期一, 十一月 28, 2022
Incidence, CR, IDL, Public health, Female, Safety, LNTH, Patient, Cardiovascular disease, Echocardiography, Liver, Center for Drug Evaluation and Research, Male, National Medical Products Administration, CDE, Intelligence, NMPA, Pharmaceutical industry, Medical imaging

Under the distribution agreement, Lantheus will supply DEFINITY to CR Double-Crane for a launch in China.

Key Points: 
  • Under the distribution agreement, Lantheus will supply DEFINITY to CR Double-Crane for a launch in China.
  • With this approval, DEFINITY is indicated in China for use in patients with suboptimal conventional echocardiography and to better identify the left ventricular endocardial border.
  • We congratulate our partner, CR Double-Crane, on the successful approval of DEFINITY in China, which further expands our global presence, said Mary Anne Heino, President and CEO, Lantheus.
  • Lantheus entered into a development and distribution arrangement with CR Double-Crane for the commercialization of DEFINITY in China, Hong Kong and Macau.

Hani Kador, MD, FACC, is recognized by Continental Who's Who

Retrieved on: 
星期二, 十一月 15, 2022
Embolism, Time-invariant system, Ventricular septal defect, ACP, Medicine, Coronary artery disease, Al-Baath University, Echocardiography, Heart, Valvular heart disease, Medical Center, Electrophysiology, MI, Cardiovascular disease, Arrhythmia, Physician, Education, Multimedia, American College of Physicians, Internal medicine, Patient, American College, Heart failure, Beaumont Health, Life, American College of Cardiology, Peripheral artery disease, Infarction, FACC, Continental, Blood, Pharmaceutical industry, Medical imaging, MD, Cardiology

With 14 years of experience in medicine, Dr. Kador is a board-certified, fellowship-trained interventional cardiologist affiliated with Eastside Cardiovascular Medicine in Roseville, MI.

Key Points: 
  • With 14 years of experience in medicine, Dr. Kador is a board-certified, fellowship-trained interventional cardiologist affiliated with Eastside Cardiovascular Medicine in Roseville, MI.
  • As an interventional cardiologist, the doctor sees patients who typically are in life and death situations.
  • He treats patients for cardiovascular disease, peripheral artery disease, arrhythmia, heart attacks, pulmonary embolisms, and blockages.
  • The field includes medical diagnosis and treatment of congenital heart defects, coronary artery disease, heart failure, valvular heart disease, and electrophysiology.

HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events

Retrieved on: 
星期四, 十一月 10, 2022
Aurora, GLOBE, Advocate Aurora Health, HSCS, NASDAQ, Patient, Arrest, AI, Virginia University, Echocardiography, MACE, Algorithm, West Virginia University, Medical device

I believe the solution to unnecessary cardiac deaths will come from low-cost, front-line screening using AI-ECGs.

Key Points: 
  • I believe the solution to unnecessary cardiac deaths will come from low-cost, front-line screening using AI-ECGs.
  • The extracted frequency parameters provided via MyoVistas CWT technology represented the majority of the statistically significant data variables used to develop the algorithm using AI-based variable reduction techniques, stated Mark Hilz, COO of HeartSciences.
  • Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences filings with the U.S. Securities and Exchange Commission at www.sec.gov.
  • Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Caption Health Receives Regulatory Approvals for Caption AI™ Technology Platform in Canada and Australia

Retrieved on: 
星期四, 十一月 10, 2022
Hospital, Fast Company, Health, JAMA Cardiology, TIME, Caption, Booth, Food, Geography, Organization, Society, Therapeutic Goods Administration, Global health, Mortality, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Heart failure, Degenerative disease, European, Cardiology, AI, Indigenous Australians, Quality assurance, Journal, Regulatory affairs, Patient, Growth, Invention, CEO, Health Canada Sodium Working Group, American Society of Echocardiography, Medical device, Echocardiography

BRISBANE, Calif., Nov. 10, 2022 /PRNewswire/ -- Caption Health, the leader in using AI and services to improve access to heart ultrasound diagnostics, announced new regulatory approvals to market its Caption AI™ technology platform from Health Canada's Medical Devices Directorate and Australia's Therapeutic Goods Administration. Echocardiography is the preferred initial imaging modality for evaluation of patients with suspected heart failure, and Caption Health expects its global growth will enable widespread access to earlier and more accurate cardiac care, especially within underserved populations and regions, as it has begun to do in the U.S.

Key Points: 
  • BRISBANE, Calif., Nov. 10, 2022 /PRNewswire/ -- Caption Health , the leader in using AI and services to improve access to heart ultrasound diagnostics, announced new regulatory approvals to market its Caption AI technology platform from Health Canada's Medical Devices Directorate and Australia's Therapeutic Goods Administration.
  • These are the second and third international regulatory approvals this year for Caption AI, following this summer's European CE Mark announcement.
  • "Our strategic global expansion is about more than market access, it's about patient access," said Steve Cashman, CEO of Caption Health.
  • The company's Caption Care services offer health providers, payers, and value-based care organizations convenient and cost-effective echos for their members, leveraging its Caption AI technology platform.

Global Coronary Heart Disease Diagnostic Imaging Devices Market Report 2022 to 2028: Rising Number of Applications of Imaging Devices Along With Increasing R&D Investments are Encouraging Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 十一月 8, 2022
Health, Cardiology, People, Degenerative disease, PET, CAD, Neck, Cardiac rehabilitation, Chest pain, Growth, Ventricular septal defect, CAGR, Risk, Technology, Medical imaging, Human, Angina, Google Images, Poverty, CT, Arrhythmia, Muscle tissue, Heartburn, Gadolinium, Heart, Arm, Oxygen, Coronary artery disease, 3D, Cardiovascular disease, Shoulder, Cholesterol, Modality, Heart failure, Artery, Incidence, MRI, SPECT, Peripheral artery disease, Ultrasound, PET/CT, Quality of life, Atherosclerosis, Echocardiography, Ischemia

The "Global Coronary Heart Disease Diagnostic Imaging Devices Market Size, Share & Industry Trends Analysis Report By Modality, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Coronary Heart Disease Diagnostic Imaging Devices Market Size, Share & Industry Trends Analysis Report By Modality, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronary Heart Disease Diagnostic Imaging Devices Market size is expected to reach $2.1 billion by 2028, rising at a market growth of 6.7% CAGR during the forecast period.
  • Chest pain, heartburn, and soreness in the shoulder, arm, back, and neck are all symptoms of coronary artery disease.
  • Coronary heart disease diagnostic imaging devices are prohibitively expensive for low-budget healthcare organizations to purchase.

Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis

Retrieved on: 
星期一, 十一月 7, 2022
Cleveland, Company, Pericarditis, Research, Virginia Commonwealth University, Heart, Recurrence, RNA transfection, C-reactive protein, Pericardial fluid, Patent, Chest pain, Cannabidiol, Cleveland Clinic, Interleukin, Agent handling, Scar, Poster, Model, Therapy, Echocardiography, NRS, TSX, Acute pericarditis, VCU, CRDL, Degenerative disease, Chronic pain, NLRP3, NASDAQ, Injection, Pericardium, Inflammation, Center, Patient, MD, Pericardial effusion, Pharmaceutical industry, Medical imaging

Oakville, Ontario--(Newsfile Corp. - November 7, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today study results demonstrating that pharmaceutically manufactured cannabidiol (the active pharmaceutical ingredient in CardiolRx™) significantly reduces pericardial effusion and thickening in a pre-clinical model of acute pericarditis and significantly suppresses the secretion of key inflammatory markers interleukin-1β ("IL-1β") and interleukin-6 ("IL-6") in vitro. The data were presented by Cardiol's research collaborators from Virginia Commonwealth University ("VCU") at The American Heart Association Scientific Sessions 2022 ("AHA2022").

Key Points: 
  • The poster entitled "Protective Effects of Pharmaceutically Manufactured Cannabidiol in a Mouse Model of Acute Pericarditis" was presented on November 5th within the "Late-Breaking Basic Science Posters" session of AHA2022.
  • Cardiol has filed comprehensive patent applications with the U.S. patent office in connection with these new findings.
  • It is recognized that pericarditis is associated with aberrant inflammasome activation, an intracellular process leading to the release of pro-inflammatory cytokines, including IL-1.
  • The Company's Phase II pilot study in recurrent pericarditis is expected to enroll 25 patients at major clinical centers in the United States specializing in pericarditis.

Tempus Launches First Cardiology Prospective Study for Its AI-Enabled Predictive Tests

Retrieved on: 
星期四, 十一月 3, 2022
Cardiology, Medical Supplies, General Health, Health, Artificial Intelligence, Medical Devices, Technology, Other Health, Precision medicine, Patient, Arrhythmia, Mortality, Therapy, Algorithm, Cardiology, Atrial flutter, AI, Degenerative disease, FDA, History, Clinical Cardiology, Stroke, SHD, Echocardiography, Health, Nature Medicine, Cardiovascular disease, TriHealth, Physician, Intelligence, Library, Risk, ECG, Wireless ambulatory ECG, Artificiality, Technology, Atrial fibrillation, Diagnosis, MPH, Medical device, Tempus, Ventricular fibrillation, MD

The study investigates whether layering a machine learning model onto a clinically acquired electrocardiogram (ECG) can make it smarter with new functionality.

Key Points: 
  • The study investigates whether layering a machine learning model onto a clinically acquired electrocardiogram (ECG) can make it smarter with new functionality.
  • Millions of Americans suffer from undiagnosed heart disease, leading to debilitating outcomes, such as stroke, that can potentially be avoided with early diagnosis.
  • Tempus AI-enabled technology aims to help clinicians find these patients.
  • Patients who have received a 12-lead ECG during routine clinical care are eligible for the study.

Viz.ai Partners with Us2.ai to Deliver AI-Enabled Echocardiography Decision Support with the Viz™ Platform

Retrieved on: 
星期三, 十一月 2, 2022
Technology, Medical Devices, Hospitals, Health Technology, Cardiology, Software, Health, Pharmaceutical, Artificial Intelligence, Algorithm, CEO, Pulmonary embolism, Automation, Partnership, Time, Hospital, Classification, 2D, Doppler effect, Disease, Degenerative disease, Echocardiography, AI, Diagnosis, Technology, Prognosis, Pulmonary hypertension, FDA, IHH Healthcare, Patient, Machine learning, Death, Cardiology, Medical device

We believe that no heart disease patient should have to wait for care when time is critical, said Chris Mansi, CEO of Viz.ai.

Key Points: 
  • We believe that no heart disease patient should have to wait for care when time is critical, said Chris Mansi, CEO of Viz.ai.
  • With a national shortage of sonographers, the combination of our leading-edge applications will support hospitals and providers as well as patients.
  • Backed by clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies.
  • The companys software tools improve clinical decision making and cardiovascular research for clinical trials using echocardiography, the safest and most common cardiac imaging modality.

Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022

Retrieved on: 
星期三, 十一月 2, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, New York Heart Association Functional Classification, Heart failure, NYHA, Echocardiography, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HCM, LVEF, Probability, FDA, LVOT, Acute coronary syndrome, Food, Heart, Percutaneous coronary intervention, Atrial fibrillation, Pharmaceutical industry, Patient

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Key Points: 
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .
  • In 2007, Pfizer and Bristol Myers Squibb entered into a worldwide collaboration to develop and commercialize apixaban, an oral anticoagulant discovered by Bristol Myers Squibb.
  • This global alliance combines Bristol Myers Squibb's long-standing strengths in cardiovascular drug development and commercialization with Pfizers global scale and expertise in this field.